Commercial sponsor Neurotrope announced it will initiate a clinical trial in children with fragile X syndrome. The company, which will conduct the trial in collaboration with the The Nemours/Alfred I. duPont Hospital for Children, in Wilmington, Delaware, have not given a date for the study’s start.

The trial will assess the safety and tolerability of Bryostatin-1, currently being tested in a Phase 2 study in patients with Alzheimer’s disease (NCT03560245).  Neurotrope has included CRO Worldwide Clinical Trials.

Source: Fragile X News Today

Pin It on Pinterest